Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40

Oppenheimer analyst Mazahir Alimohamed reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and lowers the price target from $50 to $40.